San Diego, CA · Founded 2017 · Privately Held (backing)
Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. Primmune Therapeutics is based in San Diego, CA and was founded in 2017. It was valued at $44 million at its early-stage round in Jan 2021, the last priced event on record. It has raised $63.2 million across 5 recorded rounds; the latest was a $13 million early-stage round in Oct 2020.
PMV mark · valuation
$44.0M
Oct 2026
Priced at
its early-stage round
Jan 2021
Total raised
$63.2M
Last round
Early Stage VC
Oct 2020
Cap table — not yet on record
Primmune Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Primmune Therapeutics with a free account
·Watch Primmune Therapeutics: the Monday email on marks, rounds and moves
Where does Primmune Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Primmune Therapeutics's 5 recorded funding rounds.
